Status
Conditions
Treatments
Study type
Funder types
Identifiers
About
This community-partnered study examines a technical assistance intervention designed to help permanent supportive housing agencies implement evidence-based practices to prevent tenant overdose and improve tenant health.
Full description
Homelessness and housing instability are strongly linked with overdose risk. Permanent supportive housing (PSH) -subsidized housing paired with supportive services-is a key strategy to end homelessness yet supportive housing tenants face high overdose risk due to a confluence of factors. This multi-sector, community-partnered, stepped wedge randomized controlled trial evaluates the impact of a technical assistance intervention designed to support supportive housing agencies in sustainably implementing evidence-based practices to reduce tenant overdose and improve tenant health more broadly. The technical assistance intervention will be delivered to supportive housing agencies in New Jersey and New York who are enrolled in the trial. Outcomes include PSH agency implementation of overdose prevention practices and downstream tenant overdose, substance use, and other health-related outcomes. Outcomes will be assessed using surveys, administrative data, and agency records.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
We will be enrolling supportive housing agencies from NY and NJ to participate in this study. Trial enrollment and intervention delivery will occur at the level of the agency. There are anticipated to be 24 supportive housing agencies total that will be enrolled in the study; approximately 6 agencies will be randomly assigned to each of the four intervention waves in the stepped wedge randomized controlled trial.
Inclusion Criteria:
Supportive Housing Agencies/Individuals who Work at Supportive Housing Agencies:
Tenants who Live in Supportive Housing Agencies:
Exclusion Criteria:
Primary purpose
Allocation
Interventional model
Masking
2,940 participants in 4 patient groups
Loading...
Central trial contact
Kelly Doran, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal